1. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials 
Giulia Renda, MD, PhD, Marta di Nicola, PhD, Raffaele De Caterina, MD, PhD 
The American Journal of Medicine 
Volume 128, Issue 9, Pages e2 (September 2015)
DOI: /j.amjmed
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Figure 1
RR and 95% CI of all treatment arms in the phase III trials comparing a non-vitamin K antagonist oral anticoagulants with warfarin for the overall composite outcome including unweighed ischemic stroke + systemic embolism + myocardial infarction + hemorrhagic stroke + adjusted major bleeding (major bleeding minus hemorrhagic stroke). NOAC = non-vitamin K antagonist oral anticoagulant.
The American Journal of Medicine  , e2DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions

3. Figure 2
Net clinical benefit and 95% CI of all treatment arms of non-vitamin K antagonist oral anticoagulants versus warfarin tested in phase III clinical trials for the weighed composite outcome of ischemic stroke + systemic embolism + myocardial infarction + hemorrhagic stroke + adjusted major bleeding (major bleeding minus hemorrhagic stroke). Net clinical benefit is expressed as ischemic stroke equivalents prevented per 100 person-years using ischemic stroke as the reference event (weight = 1). CI = confidence interval; IS = ischemic stroke; NNT = number needed to treat (to prevent all grouped events included in the net clinical benefit evaluation, per year of treatment); NOAC = non-vitamin K antagonist oral anticoagulant.
The American Journal of Medicine  , e2DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions

4. Figure E1
RR and 95% CI of all treatment arms versus warfarin for the composite outcome including unweighed ischemic stroke + systemic embolism + myocardial infarction + hemorrhagic stroke + adjusted major bleeding (major bleeding minus hemorrhagic stroke) + all-cause death in the 4 phase III trials of a non-vitamin K antagonist oral anticoagulant versus warfarin in nonvalvular atrial fibrillation. Contrary to the analyses presented in the article, the current analysis has to be considered exploratory, because it may include nonmutually exclusive events. NOAC = non-vitamin K antagonist oral anticoagulant.
The American Journal of Medicine  , e2DOI: ( /j.amjmed )
Copyright © 2015 Elsevier Inc. Terms and Conditions